Table 1 Clinical and demographic characteristics of the study cohort
Demographic/clinical variable | All patients | Excluding patients with SVR |
|---|---|---|
No. | 243 | 153 |
Male sex | 182 (74.9%) | 118 (77.1%) |
Age—year | 40.7 (37.7–44.8) | 41.6 (38.2–45) |
Prior injection drug use | 209 (86%) | 132 (86.3%) |
Current alcohol intake > 50 g/d | 30 (12.3%) | 21 (13.7%) |
CDC category C | 73 (30.2%) | 56 (36.8%) |
CD4+ T cells nadir—n/mm3 | 189 (77–306) | 169 (59–273) |
cART | 198 (81.5%) | 122 (79.7%) |
Undetectable HIV viral load | 178 (74.2%) | 110 (73.3%) |
Baseline CD4+ T cells—n/mm3 | 485 (346–679) | 468 (340–667) |
HCV genotype | ||
1.4 | 180 (76.9%) | 129 (87.8%) |
2.3 | 54 (23.1%) | 18 (12.2%) |
HCV-RNA ≥ 500,000 IU/mL | 174 (78.4%) | 113 (81.5%) |
METAVIR fibrosis stage (n = 210) | ||
F0 or F1 | 109 (45.9%) | 77 (50.3%) |
F2 | 61 (25.1%) | 35 (22.9%) |
F3 | 20 (8.2%) | 11 (7.2%) |
F4 | 21 (8.6%) | 11 (7.2%) |
N/A | 32 (13.2%) | 19 (12.4%) |
FIB-4 − median (IQR) | 1.46 (1.03–2.06) | 1.43 (1.08–1.92) |
FIB-4 ≥ 3.25 | 24 (9.9%) | 14 (9.2%) |